𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

✍ Scribed by John D. Roberts; Stephen Shibata; Darcy V. Spicer; Howard L. McLeod; Mary Beth Tombes; Brenda Kyle; Mary Carroll; Beth Sheedy; Mary A. Collier; Yazdi K. Pithavala; Linda J. Paradiso; Neil J. Clendeninn

Publisher
Springer
Year
2000
Tongue
English
Weight
95 KB
Volume
45
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase I study of raltitrexed and pacli
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors
✍ Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Ma πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 66 KB πŸ‘ 2 views

## BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of a

A Phase II study of intravenous exatecan
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma
✍ Francisco J. Esteva; Edgardo Rivera; Massimo Cristofanilli; Vicente Valero; Mela πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 111 KB

## Abstract ## BACKGROUND The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline‐resistant and taxane‐resistant, metastatic breast carcinoma. ## METHODS All patients had clinical evi